A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach.
Antibodies
Gefitinib
LC–MS/MS
Protein interactions
SW480
Tyrosine kinase inhibitors
Journal
Proteome science
ISSN: 1477-5956
Titre abrégé: Proteome Sci
Pays: England
ID NLM: 101170539
Informations de publication
Date de publication:
16 May 2022
16 May 2022
Historique:
received:
15
01
2022
accepted:
24
04
2022
entrez:
16
5
2022
pubmed:
17
5
2022
medline:
17
5
2022
Statut:
epublish
Résumé
The epidermal growth factor receptor (EGFR) overexpression is found in metastatic colorectal cancer (mCRC). Targeted molecular therapies such as monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI) are becoming more precise, targeting specifically for cancer therapeutics. However, there are adverse effects of currently available anti-EGFR drugs, including drug-resistant and side effects. Nanobodies can overcome these limitations. Our previous study has found that cell-penetrable nanobodies targeted at EGFR-tyrosine kinase were significantly reduced EGFR-positive lung cancer cells viability and proliferation. The aim of the present study was to determine the effect of cell-penetrable nanobody (R9VH36) on cell viability and proteomic profile in EGFR-positive human colorectal cancer cell lines. The human colorectal carcinoma cell line (SW480) was treated with R9VH36, compared with gefitinib. Cell viability was monitored using the MTT cell viability assay. The proteomic profiling was analyzed by LC-MS/MS . The half-maximal inhibitory concentration (IC The proteomics explored those 6,626 proteins had different expressions between R9VH36 and gefitinib. There were 8 proteins in R9VH36 exhibited opposite expression direction when comparing to gefitinib. Our findings suggest that R9VH36 has the potential to be an alternative remedy for treating EGFR-positive colon cancer.
Sections du résumé
BACKGROUND
BACKGROUND
The epidermal growth factor receptor (EGFR) overexpression is found in metastatic colorectal cancer (mCRC). Targeted molecular therapies such as monoclonal antibodies (mAbs) and tyrosine kinase inhibitors (TKI) are becoming more precise, targeting specifically for cancer therapeutics. However, there are adverse effects of currently available anti-EGFR drugs, including drug-resistant and side effects. Nanobodies can overcome these limitations. Our previous study has found that cell-penetrable nanobodies targeted at EGFR-tyrosine kinase were significantly reduced EGFR-positive lung cancer cells viability and proliferation. The aim of the present study was to determine the effect of cell-penetrable nanobody (R9VH36) on cell viability and proteomic profile in EGFR-positive human colorectal cancer cell lines.
METHODS
METHODS
The human colorectal carcinoma cell line (SW480) was treated with R9VH36, compared with gefitinib. Cell viability was monitored using the MTT cell viability assay. The proteomic profiling was analyzed by LC-MS/MS .
RESULTS
RESULTS
The half-maximal inhibitory concentration (IC
CONCLUSION
CONCLUSIONS
The proteomics explored those 6,626 proteins had different expressions between R9VH36 and gefitinib. There were 8 proteins in R9VH36 exhibited opposite expression direction when comparing to gefitinib. Our findings suggest that R9VH36 has the potential to be an alternative remedy for treating EGFR-positive colon cancer.
Identifiants
pubmed: 35578244
doi: 10.1186/s12953-022-00190-6
pii: 10.1186/s12953-022-00190-6
pmc: PMC9109347
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9Subventions
Organisme : Royal Golden Jubilee (RGJ) Ph.D. Programme
ID : PHD/0152/2557
Organisme : Royal Golden Jubilee (RGJ) Ph.D. Programme
ID : PHD/0152/2557
Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2014 Apr 16;9(4):e93046
pubmed: 24740004
J Biol Chem. 2004 Mar 12;279(11):10756-64
pubmed: 14679214
Adv Cancer Res. 2018;138:71-98
pubmed: 29551130
J Hematol Oncol. 2020 Oct 27;13(1):143
pubmed: 33109256
Int J Cancer. 2011 Oct 15;129(8):2013-24
pubmed: 21520037
J Transl Med. 2015 Jul 07;13:217
pubmed: 26149458
Sci Rep. 2018 Jan 12;8(1):663
pubmed: 29330539
Anticancer Res. 2011 Jun;31(6):2149-60
pubmed: 21737635
J Proteome Res. 2007 Jan;6(1):399-408
pubmed: 17203985
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
World J Gastroenterol. 2014 Jun 28;20(24):7602-21
pubmed: 24976699
J Biomed Biotechnol. 2011;2011:165214
pubmed: 21687596
Nat Methods. 2007 Mar;4(3):207-14
pubmed: 17327847
EMBO J. 2000 Jul 3;19(13):3159-67
pubmed: 10880430
Crit Rev Oncol Hematol. 2019 Nov;143:153-163
pubmed: 31678702
Nucleic Acids Res. 2013 Jan;41(Database issue):D1063-9
pubmed: 23203882
J Biomed Sci. 2020 Jan 2;27(1):1
pubmed: 31894001
Foods. 2021 Sep 12;10(9):
pubmed: 34574267
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3621-3630
pubmed: 31468992
Cancers (Basel). 2020 Jun 28;12(7):
pubmed: 32605298
Cancer Treat Rev. 2017 Feb;53:79-97
pubmed: 28088073
Cancer. 2019 Dec 1;125(23):4139-4147
pubmed: 31433498
J Cell Biochem. 2019 Oct;120(10):18077-18087
pubmed: 31172597
Oncogene. 2009 Aug;28 Suppl 1:S24-31
pubmed: 19680293
Adv Cancer Res. 2000;77:25-79
pubmed: 10549355
Tumour Biol. 2000 Mar-Apr;21(2):105-15
pubmed: 10686540
J Agric Food Chem. 2014 Jan 8;62(1):58-65
pubmed: 24344900
EJNMMI Res. 2021 Jan 19;11(1):6
pubmed: 33464410